10/31/2018: Correction to Previous Briefing
CodeMap® Compliance Briefing: 10/31/2018
Editor's Correction: Our 10/4/2018 Compliance Briefing described significant changes to the codes and payment amounts for BRCA1 and BRCA2 gene tests for hereditary breast and ovarian cancer. The final analysis of Medicare payment for full BRCA1/BRCA2 sequence and deletion/duplication testing assumed that existing CPT code 81162 would be deleted from the 2019 CPT. This was incorrect.
The 2019 CPT still includes 81162 with only a minor revision to the description and instructs that it is to be used to report full BRCA1/BRCA2 sequence and deletion/duplication testing when performed on the same date of service.
This means that the present Medicar....
Sorry, access to this content requires a current subscription.
Click here for publications catalog.
All information contained in the CodeMap® website, CodeMap® training modules, CodeMap® publications, CodeMap® Data Files, and CodeMap® newsletters, briefings and reports is copywritten and may not be reproduced, redistributed, or sold without express written permission of CodeMap®.